<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="379">
  <stage>Registered</stage>
  <submitdate>2/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000369628</actrnumber>
  <trial_identification>
    <studytitle>A Double-Blind, Randomised, Single Centre, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of a Single Subcutaneous Implant of EPT 1647 in Patients Suffering from Recurrent Polymorphous Light Eruption</studytitle>
    <scientifictitle>A Double-Blind, Randomised, Single Centre, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of a Single Subcutaneous Implant of EPT 1647 in Patients Suffering from Recurrent Polymorphous Light Eruption</scientifictitle>
    <utrn />
    <trialacronym>EP012</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Polymorphous Light Eruption (PMLE)</healthcondition>
    <conditioncode>
      <conditioncode1>Skin</conditioncode1>
      <conditioncode2>Dermatological conditions</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>EPT1647 - 6 months</interventions>
    <comparator />
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine whether EPT 1647 implants given as a prophylactic can prevent or reduce the occurrence of symptoms like urticaria, vesiculation, papules, eczema, erithema, itching and burning associated with PMLE</outcome>
      <timepoint>Reviewed at each monthly visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To establish the safety and tolerability as judged from observed Adverse Events, of a sustained release implant of EPT 1647 delivering approximately 20 mg over a 10 day period in Caucasian participants with a history of recurrent Polymorphous Light Eruption (PMLE).</outcome>
      <timepoint>Over 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>History of PMLE.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>History of skin cancer.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed code break envelopes</concealment>
    <sequence>Sequence generated by Random.org which uses atmospheric noises to randomisation numbers. The sequence is completely random therefore no restriction method was used.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>12/09/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Epitan Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Epitan Limited</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Chris Baker and Dr Peter Foley</name>
      <address>St Vincents Hospital
Melbourne VIC 3065</address>
      <phone>+61 3 92882211</phone>
      <fax />
      <email>baker.c@bigpond.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Chris Baker and Dr Peter Foley</name>
      <address>St Vincents Hospital
Melbourne VIC 3065</address>
      <phone>+61 3 92882211</phone>
      <fax />
      <email>baker.c@bigpond.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>